Psychobiotics, live microorganisms that provide mental health by interacting with the gut microbiota, are emerging as a promising therapeutic option for psychiatric and neurodevelopmental disorders. Their effectiveness in addressing conditions such as depression, anxiety, insomnia, stress, autism spectrum disorder (ASD), and eating disorders were examined through a comprehensive analysis of existing studies up to the first half of 2024, based on data from reliable electronic databases. We found that psychobiotics can significantly reduce symptoms of various psychiatric disorders by influencing neurotransmitter levels, regulating the hypothalamic-pituitary-adrenal (HPA) axis, and improving gut barrier function through short-chain fatty acids (SCFAs) and other metabolites. However, several limitations were identified, including inconsistent study methodologies, small sample sizes, and a lack of data on long-term safety. Addressing these limitations through rigorous research is essential for establishing standardized protocols and fully confirming the therapeutic potential of psychobiotics. In conclusion, psychobiotics show great promise as complementary treatments for mental health conditions, but continued research is necessary to refine their application and integrate them into clinical practice effectively.
29 April 2026 in Endocrine, Metabolic & Immune Disorders - Drug Targets
Aims: This meta-analysis aims to evaluate the efficacy and safety of probiotic supplementation as an adjunct to standard therapy in patients with type 2 diabetes (T2D), with a focus on its effects on plasma glucose, HbA1c, and insulin levels. Methods: Specific keywords such as “Type 2 Diabetes”, “Probiotics”, and “Blood Sugar” were employed to identify relevant clinical and randomized controlled trials. A comprehensive search of PubMed, Scopus, and Web of Science, conducted between September 2010 and October 2024, retrieved 48 studies, of which only 9 met the predefined inclusion criteria. Studies were excluded if they did not involve patients with T2D, failed to specify the probiotic strains used, lacked a placebo-controlled arm, were not written in English, were not freely accessible, or did not report outcomes of interest. Discussion and conclusion: This meta-analysis included a total of 649 patients with T2D, who showed a reduction in levels of some clinical indicators at the end of the intervention period. These findings provide evidence supporting the use of probiotic supplementation as an adjunct to standard therapy for the management of this condition